A Phase 4 interventional study of Butylphthalide and Sodium Chloride Injection and Saline Solution in Butylphthalide, Cardiac Arrest and Neuroprotective Drugs, sponsored by Tang Ziren. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Tang Ziren · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.
Among the 37 studies in Heart Arrest with a site in China, this one is one of 4 that started in 2021, is one of 2 in phase 4, reaches primary completion later than 9 of the 21 other live ones, and was the 23rd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
Central China Fuwai Hospital of Zhengzhou University · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–75
Tang Ziren · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 299 across the 9 interventional studies, 300 across the 28 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Tang Ziren is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Tang Ziren has 5 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Arrest with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07113769Central China Fuwai Hospital of Zhengzhou UniversityPlasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation | 2026-12-30 |
| NCT06353334Tang ZirenButylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) | 2026-12-31 |
| NCT06974682Capital Medical UniversityEffect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest | 2027-06-01 |
| NCT06992843Xiangya Hospital of Central South UniversityNeuroprotection Bundles For Comatose Survivors Following Cardiac Arrest | 2027-08 |
| NCT06241261The University of Hong KongArresting Early Childhood Caries With a Silver Diamine Fluoride Gel | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Arrest with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days
Drug: Butylphthalide and Sodium Chloride Injection
Saline Solution 100ml ivgtt bid 14days
Drug: Saline Solution
Drug pages: ButylphthalideStudies of ButylphthalideButylphthalide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Sodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
The proportion of patients with a CPC score of 1-2
The primary outcome is the proportion of patients with a CPC score of 1-2 at 90days after randomization in each group. Favourable: 1 means full recovery or mild disability, 2 means moderate disability but independent in activities of daily living (ADLs). Unfavourable: 3 means severe disability-Dependent in ADLs, 4 means persistent vegetive state, 5 means Death.
Time frame: 90 days
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Starting 6 months after publication
Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Butylphthalide · Sodium Chloride
Tang Ziren